Benitec Biopharma: ASX Spotlight Series (NY, Mar 2015)

Company Presentations

by Carolyn Herbert

Benitec Biopharma Limited (ASX:BLT) Chief Business Officer Carl Stubbings presents at ASX Spotlight Series in New York. 
 
The biotechnology company’s presentation is titled, “Gene Silencing: A quiet revolution in healthcare”. 
 
Mr Stubbings provides a financial snapshot and investment case for Benitec Biopharma while outlining the group’s operations. 
 
Summarising the presentation Mr Stubbings says, “We are developing a technology... with our lead indication TT 034 being a disruptive technology in what we believe will remain a significant market. 
 
Potentially we can provide a cure for a wide range of diseases; we have over 100 patents around the technology and specific diseases themselves. 
 
We have an extensive pipeline of programs, as I’ve said previously, any one of which could be a company maker.” 

Carolyn Herbert

Finance News Network
Carolyn joined FNN in August 2015 as the Head of News and also presented the Market at Midday and the Market Wrap. With more than five years of broadcast journalism experience, Carolyn has worked as a finance anchor on the Sky News Business channel and as an anchor and reporter for ABC News. She is also a qualified corporate lawyer specialising in IPOs, takeovers and mergers and acquisitions.